Neurology 2002;58:1333-1337
© 2002 American Academy of Neurology
Statins and risk of polyneuropathy
A case-control study
D. Gaist, MD PhD,
U. Jeppesen, MD PhD,
M. Andersen, MD PhD,
L. A. García Rodríguez, MD MSc,
J. Hallas, MD PhD and
S. H. Sindrup, MD PhD
From the Department of Neurology (Drs. Gaist, Jeppesen, and Sindrup), Odense University Hospital; Epidemiology (Dr. Gaist) and Clinical Pharmacology (Drs. Andersen, Hallas, and Sindrup), Institute of Public Health, University of Southern Denmark; and Centro Español de Investigación Farmacoepidemiológica (Dr. García Rodríguez), Madrid, Spain.
Address correspondence and reprint requests to Dr. David Gaist, Epidemiology, Institute of Public Health, University of Southern Denmark, Sdr Boulevard 23A, 5000 Odense C, Denmark; e-mail: dgaist{at}health.sdu.dk or dg@dadlnet.dk
Background: Several case reports and a single epidemiologic study indicate that use of statins occasionally may have a deleterious effect on the peripheral nervous system. The authors therefore performed a population-based study to estimate the relative risk of idiopathic polyneuropathy in users of statins.
Method: The authors used a population-based patient registry to identify first-time-ever cases of idiopathic polyneuropathy registered in the 5-year period 1994 to 1998. For each case, validated according to predefined criteria, 25 control subjects were randomly selected among subjects from the background population matched for age, sex, and calendar time. The authors used a prescription register to assess exposure to drugs and estimated the odds ratio of use of statins (ever and current use) in cases of idiopathic polyneuropathy compared with control subjects.
Results: The authors verified a diagnosis of idiopathic polyneuropathy in 166 cases. The cases were classified as definite (35), probable (54), or possible (77). The odds ratio linking idiopathic polyneuropathy with statin use was 3.7 (95% CI 1.8 to 7.6) for all cases and 14.2 (5.3 to 38.0) for definite cases. The corresponding odds ratios in current users were 4.6 (2.1 to 10.0) for all cases and 16.1 (5.7 to 45.4) for definite cases. For patients treated with statins for 2 or more years the odds ratio of definite idiopathic polyneuropathy was 26.4 (7.8 to 45.4).
Conclusions: Long-term exposure to statins may substantially increase the risk of polyneuropathy.
This article has been cited by other articles:
|
|
|
|
 
M C Dalakas
Toxic and drug-induced myopathies
J. Neurol. Neurosurg. Psychiatry,
August 1, 2009;
80(8):
832 - 838.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. H. Samson
The Role of Statin Drugs in the Management of the Peripheral Vascular Patient
Vascular and Endovascular Surgery,
August 1, 2008;
42(4):
352 - 366.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. E. Tinetti
Over-the-Counter Sales of Statins and Other Drugs for Asymptomatic Conditions
N. Engl. J. Med.,
June 19, 2008;
358(25):
2728 - 2732.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. R. Holman
Some Docs in Denial About Statin Side Effects
DOC News,
December 1, 2007;
4(12):
1 - 12.
[Full Text]
|
|
|
|
|
|
|
L. Mascitelli and F. Pezzetta
EPIDEMIOLOGY OF DISTAL SYMMETRICAL NEUROPATHIES IN THE ITALIAN ELDERLY
Neurology,
October 23, 2007;
69(17):
1728 - 1728.
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. Ravnskov, P. J Rosch, M. C Sutter, and M. C Houston
Should we lower cholesterol as much as possible?
BMJ,
June 3, 2006;
332(7553):
1330 - 1332.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. B. Vaughan and D. S.H. Bell
Statin Neuropathy Masquerading as Diabetic Autoimmune Polyneuropathy
Diabetes Care,
August 1, 2005;
28(8):
2082 - 2082.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Auer, G. Lamm, B. Eber, C. P. Cannon, S. A. Murphy, E. Braunwald, U. Ravnskov, P. J. Rosch, M. C. Sutter, G. A. Modest, et al.
Intensive lipid lowering with atorvastatin in coronary disease.
N. Engl. J. Med.,
July 7, 2005;
353(1):
93 - 96.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Corrao, A. Zambon, L. Bertu, E. Botteri, O. Leoni, and P. Contiero
Lipid lowering drugs prescription and the risk of peripheral neuropathy: an exploratory case-control study using automated databases
J Epidemiol Community Health,
December 1, 2004;
58(12):
1047 - 1051.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Mo and C. E. Elson
Studies of the Isoprenoid-Mediated Inhibition of Mevalonate Synthesis Applied to Cancer Chemotherapy and Chemoprevention
Exp Biol Med,
July 1, 2004;
229(7):
567 - 585.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B.A. Golomb, T. Kane, and J.E. Dimsdale
Severe irritability associated with statin cholesterol-lowering drugs
QJM,
April 1, 2004;
97(4):
229 - 235.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. MacDonald and M. M. Halleck
The Toxicology of HMG--CoA Reductase Inhibitors: Prediction of Human Risk
Toxicol Pathol,
February 1, 2004;
32(2_suppl):
26 - 41.
[Abstract]
[PDF]
|
|
|
|
|
|
|
B. A. Golomb, M. H. Criqui, H. White, and J. E. Dimsdale
Conceptual Foundations of the UCSD Statin Study: A Randomized Controlled Trial Assessing the Impact of Statins on Cognition, Behavior, and Biochemistry
Arch Intern Med,
January 26, 2004;
164(2):
153 - 162.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Silverberg
Atorvastatin-Induced Polyneuropathy
Ann Intern Med,
November 4, 2003;
139(9):
792 - 793.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M Backes and P. A Howard
Association of HMG-CoA Reductase Inhibitors with Neuropathy
Ann. Pharmacother.,
February 1, 2003;
37(2):
274 - 278.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Weinhofer, S. Forss-Petter, M. Zigman, and J. Berger
Cholesterol regulates ABCD2 expression: implications for the therapy of X-linked adrenoleukodystrophy
Hum. Mol. Genet.,
October 15, 2002;
11(22):
2701 - 2708.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Is Statin Use Associated with Polyneuropathy?
Journal Watch Neurology,
September 6, 2002;
2002(906):
4 - 4.
[Full Text]
|
|
|
|
|
|
|
R. C. Pasternak, S. C. Smith Jr, C. N. Bairey-Merz, S. M. Grundy, J. I. Cleeman, and C. Lenfant
ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins
Stroke,
September 1, 2002;
33(9):
2337 - 2341.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. C. Pasternak, S. C. Smith Jr, C. N. Bairey-Merz, S. M. Grundy, J. I. Cleeman, C. Lenfant, and Writing Committee Members:
ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins
Circulation,
August 20, 2002;
106(8):
1024 - 1028.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. C. Pasternak, S. C. Smith Jr, C. N. Bairey-Merz, S. M. Grundy, J. I. Cleeman, and C. Lenfant
ACC/AHA/NHLBI clinical advisory on the use and safety of statins
J. Am. Coll. Cardiol.,
August 7, 2002;
40(3):
567 - 572.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Statins and Peripheral Neuropathy
Journal Watch Cardiology,
June 14, 2002;
2002(614):
5 - 5.
[Full Text]
|
|
|
|
|
|
|
Statins and Peripheral Neuropathy
Journal Watch (General),
May 28, 2002;
2002(528):
2 - 2.
[Full Text]
|
|
|
|
|
|
|
M. Donaghy
Assessing the risk of drug-induced neurologic disorders: Statins and neuropathy
Neurology,
May 14, 2002;
58(9):
1321 - 1322.
[Full Text]
[PDF]
|
|
|
|
